IP Library Granted Patent US 11,110,175
Granted Patent B2
US 11,110,175 · App. 15/749,951 · Granted Sep 7, 2021

Compositions with permeation enhancers for drug delivery

Inventors: Daniel S. Kohane (Newton, MA); Rong Yang (Cambridge, MA); Lily Yun Lin (Austin, TX)
Assignees: Children's Medical Center Corporation; Massachusetts Institute of Technology
A61K47/34A61K9/0046A61K9/06A61K31/407A61K31/424A61K31/431A61K31/445A61K31/4709A61K31/496A61K31/5383A61K31/573A61K38/12A61K45/06A61K47/06A61K47/10A61K47/12A61K47/20A61K47/22A61K47/26A61P27/16A61P31/04C08G65/3355C08G79/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,175
App. No.
15/749,951
Granted
Sep 7, 2021
Kind
B2
Abstract

The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.

Claims (98)

1. A composition comprising:

(a) an antibiotic or a combination of antibiotics, wherein each antibiotic is a β-lactamase inhibitor or has a molecular weight of about 290 g/mol to about 749 g/mol;

(b) a permeation enhancer or a combination of permeation enhancers selected from the group consisting of limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, and ethylpiperazine carboxylate; and a permeation enhancer with a molecular weight of about 232 g/mol to about 1310 g/mol; wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and

(c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer;

wherein:

the composition forms a gel at temperatures above a phase transition temperature; and

the phase transition temperature is less than about 37° C.;

and at least one of conditions (i), (ii), and (iii) are met:

(i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5° C.;

(ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition or greater than about 500 Pa, whichever is smaller, at a temperature of about 37° C.; and

(iii) the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition at a temperature of about 37° C.;

wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers;

wherein the polymer comprises a polymer of Formula (I′):

wherein:

each occurrence of Y is independently —R 1 or -L 2 R 2 ;

each occurrence of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl;

each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene;

each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR b , —N(R b ) 2 , or an oxygen protecting group;

each occurrence of R 3 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, —OR b , or —N(R) 2 ;

each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring;

each of G 1A and G 2A is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and

each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

2. A composition comprising:

(a) an antibiotic or a combination of antibiotics, wherein each antibiotic is a β-lactamase inhibitor or has a molecular weight of about 290 g/mol to about 749 g/mol;

(b) a permeation enhancer or a combination of permeation enhancers selected from the group consisting of limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, and ethylpiperazine carboxylate; and a permeation enhancer with a molecular weight of about 232 g/mol to about 1310 g/mol; and

(c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer;

wherein:

the composition forms a gel at temperatures above a phase transition temperature; and

the phase transition temperature is less than about 37° C.;

and at least one of conditions (i), (ii), and (iii) are met:

(i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5° C.;

(ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition at a temperature of about 37° C.; and

(iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37° C.;

wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers;

wherein the polymer comprises a polymer of Formula (I′):

wherein:

each occurrence of Y is independently —R 1 or -L 2 R 2 ;

each occurrence of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl;

each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene;

each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR b , —N(R b ) 2 , or an oxygen protecting group;

each occurrence of R 3 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, —OR b , or —N(R) 2 ;

each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring;

each of G 1A and G 2A is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and

each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

3. A matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula (I′):

wherein:

each occurrence of Y is independently —R 1 or -L 2 R 2 ;

each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl;

each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene;

each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR b , —N(R b ) 2 , or an oxygen protecting group;

each occurrence of R 3 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, —OR b , or —N(R) 2 ;

each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring;

each of G 1A and G 2A is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and

each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

4. The polymer of claim 3 , wherein the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula:

wherein:

each occurrence of Z is independently —R 4 ;

each occurrence of R 4 is independently optionally substituted alkyl;

each of G 1A and G 2A is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and

each of p, q, r, s, and t is independently an integer between 1 and 200, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1;

the composition forms a gel at temperatures above a phase transition temperature; and

the phase transition temperature is less than about 37° C.;

and at least one of conditions (i), (ii), and (iii) are met:

(i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5° C.;

(ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition at a temperature of about 37° C.; and

(iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37° C.;

wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers.

5. The polymer of claim 3 , wherein the polymer is of the formula:

6. The polymer of claim 3 , wherein the polymer is of the formula:

7. The polymer of claim 3 , further comprising an antibiotic that is a β-lactamase inhibitor or has a molecular weight of about 290 g/mol to about 749 g/mol.

8. The composition of claim 3 , wherein the polymer further comprises blocks selected from the group consisting polyethylene oxide, polypropylene oxide, poloxamers, poloxamer 407, poloxamer 188, poloxamines, methylcellulose, hydroxypropyl methylcellulose, ethyl(hydroxyethyl) cellulose, xyloglucan, acetates, phthalates, latex, poly(acrylic acid), N-isopropylacrylamides, cellulose, chitosan, dextran, and hyaluronic acid, and derivatives thereof.

9. The composition of claim 3 , wherein the polymer comprises phosphoester monomers of Formula (M):

wherein for each monomer Y is independently —R 1 or -L 2 R 2 , wherein:

each occurrence of R 1 is independently optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;

each occurrence of L 2 is independently optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene;

each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR b , —N(R b ) 2 ; and

each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring.

10. The composition of claim 1 , wherein the polymer is of formula:

wherein:

each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;

each occurrence of R 3 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, —OR b , or —N(R b ) 2 ; and

each of G 1A and G 2A is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group.

11. The composition of claim 10 , wherein each R 1 is unsubstituted C 1-20 alkyl.

12. The composition of claim 1 , wherein each L 2 is a bond or unsubstituted C 1-6 alkylene.

13. The composition of claim 12 , wherein each L 2 is a bond.

14. The composition of claim 12 , wherein each L 2 is unsubstituted C 1-6 alkylene.

15. A kit for treating an ear disease comprising a container, a composition of claim 1 , and instructions for administering the composition to a subject in need thereof.

16. The composition of claim 1 , wherein each instance of Y is R 1 .

17. The composition of claim 16 , wherein R 1 is optionally substituted alkyl.

18. The composition of claim 17 , wherein R 1 is optionally substituted C 1-6 alkyl.

19. The composition of claim 1 , wherein each of p and t is an integer between 1 and 100, inclusive.

20. The composition of claim 17 , wherein each of p and t is an integer between 1 and 10, inclusive.

21. The composition of claim 19 , wherein r is an integer between 10 and 100, inclusive.

22. The polymer of claim 3 , wherein the polymer is of the formula:

23. The composition of claim 1 , wherein the polymer is of the formula:

24. The composition of claim 1 , wherein the polymer is of the formula:

25. The composition of claim 2 , wherein the polymer is of the formula:

26. The composition of claim 2 , wherein the polymer is of the formula:

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 29, 2019
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048180/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: LIN, LILY YUN
To: CHILDREN'S MEDICAL CENTER CORPORATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 045741/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: KOHANE, DANIEL S.; YANG, RONG
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 045741/0285 →
Continuity (2)
Provisional Application 62201199 · Aug 5, 2015
Related Publication 20180228903A1 · Aug 16, 2018